Medicus Pharma Ltd. (MDCX) Seeks FDA OK for Seamless Teverelix Phase 2b/3 To Enable Partnering

Medicus Pharma submitted an optimized seamless Phase 2b/3 protocol to the FDA for Teverelix in advanced prostate cancer, aiming to cut planned enrollment to ~600 from ~1,500 and enable partnering, subject to FDA feedback.Material DetailsContext by AI AnalystThis is an early regulatory step to strea…